Immunitas Therapeutics Presents Preclinical Data on IMT-380, a First-in-Class Anti-CD161 Antibody, at FASEB Science Research Conference on Autoimmunity
By SquaredTown on July 30, 2025
IMT-380 induces selective depletion of pathogenic CD161+ T cells, reducing inflammatory cytokine expression across in vitro and in vivo autoimmune disease models Presented data support anti-CD161 therapy as a novel approach for the treatment of autoimmune diseases WALTHAM, Mass., July 30,...